Abstract
Antisense technologies are widely used for the inhibition of gene expression. Although traditionally the AUG start codon of the open reading frame is targeted to disrupt ribosome assembly and initiation, an emerging approach is targeting sequences to disrupt pre-mRNA splicing. The primary advantage to using this approach is a positive read-out for an antisense effect through detection of a novel splice product, but additional benefit can be found in generating a novel splice product with altered functional properties. The antisense compounds used here are phosphorodiamidate morpholino oligomers conjugated to an arginine-rich cell penetrating peptide (P-PMO). We describe a five-step process for selecting the best candidate antisense compound for altering IL-12Rb2 expression including (1) detecting mRNA splice products by RT-PCR, (2) measuring protein expression, (3) evaluating protein function, (4) checking cellular viability, and (5) validating efficacy of the final candidate compound. The significance of targeting exons composed of a number of base pairs divisible by 3 is also discussed. The five steps described here for selecting the best candidate P-PMO to alter IL-12Rb2 expression should be applied for designing and screening antisense compounds for other gene targets.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Marshall, N. B., Oda, S. K., London, C. A., Moulton, H. M., Iversen, P. L., Kerkvliet, N. I., and Mourich, D. V. (2007) Arginine-rich cell-penetrating peptides facilitate delivery of antisense oligomers into murine leukocytes and alter pre-mRNA splicing. J Immunol Methods 325, 114–26.
Mourich, D. V., Oda, S. K., London, C. A., Marshall, N. B., Schnell, F. J., Hauck, L., Hinrichs, D. J., and Iversen, P. (2010, submitted) Ligand independent form of CTLA-4 induced by antisense EXON skipping in NOD mouse inhibits autoimmune diabetes J. Immunol.
Chang, Y. F., Imam, J. S., and Wilkinson, M. F. (2007) The nonsense-mediated decay RNA surveillance pathway. Annu Rev Biochem 76, 51–74.
Vijayakrishnan, L., Slavik, J. M., Illes, Z., Greenwald, R. J., Rainbow, D., Greve, B., Peterson, L. B., Hafler, D.A., Freeman, G. J., Sharpe, A. H., Wicker, L. S., and Kuchroo, V. K. (2004) An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells. Immunity 20, 563–75.
Acknowledgments
We would like to acknowledge the technical assistance of Margaret Lubkin, and recognize the Cell and Tissue Analysis Facilities and Service Core of the Environmental Health Sciences Center and Center for Genome Research and Biocomputing at Oregon State University.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Marshall, N.B., Hauck, L.L., Mourich, D.V. (2011). Five-Step Process for Screening Antisense Compounds for Efficacy: Gene Target IL-12Rb2. In: Goodchild, J. (eds) Therapeutic Oligonucleotides. Methods in Molecular Biology, vol 764. Humana Press. https://doi.org/10.1007/978-1-61779-188-8_10
Download citation
DOI: https://doi.org/10.1007/978-1-61779-188-8_10
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-187-1
Online ISBN: 978-1-61779-188-8
eBook Packages: Springer Protocols